Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4184-4190

  Gisselbrecht, Christian ^a   Glass, Bertram ^a   Mounier, Nicolas ^a   Gill, Devinder Singh ^a   Linch, David C ^a   Trneny, Marek ^a   Bosly, Andre ^a   Ketterer, Nicolas ^a   Shpilberg, Ofer ^a   Hagberg, Hans ^a   Ma, David ^a   Brière, Josette ^a   Moskowitz, Craig H ^a   Schmitz, Norbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AUSTRALIA; AUTOTRANSPLANTATION; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EUROPE; IMMUNOLOGY; ISRAEL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; EUROPE; FEMALE; HUMANS; IFOSFAMIDE; ISRAEL; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEW YORK CITY; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957965500     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1618     Document Type: Article

References (22)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
2. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
3. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
4. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
5. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
6. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
7. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987 (Pubitemid 17076232)
8. Guglielmi C, Gomez F, Philip T, et al: Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 16:3264-3269, 1998 (Pubitemid 28481620)
9. Blay J, Gomez F, Sebban C, et al: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 92:3562-3568, 1998 (Pubitemid 28525180)
10. Hamlin PA, Zelenetz AD, Kewalramani T, et al: Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-1996, 2003
11. Vellenga E, van Putten WL, van't Veer MB, et al: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood 111:537-543, 2008
12. Gisselbrecht C: Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 143:607-621, 2008
13. Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004 (Pubitemid 38596282)
14. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988 (Pubitemid 18050400)
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
17. Cox DR: Regression model and life tables. J R Stat Soc B 34:187-220, 1972
18. Khouri IF, Saliba RM, Hosing C, et al: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23:2240-2247, 2005 (Pubitemid 46218716)
19. Martín A, Conde E, Arnan M, et al: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome - A GEL/TAMO study. Haematologica 93:1829-1836, 2008
20. Thieblemont C, Gisselbrecht C: Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep 11:386-393, 2009
21. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
22. Glass B, Hasenkamp J, Anke Goerlitz A, et al: Allogeneic stem cell transplantation with intermediate conditioning is effective in high risk relapse and progressive disease of aggressive non-Hodgkin lymphoma. Blood 114:3379, 2009 (abstr 3379)